MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin

Cancer Cell

Volumn 28, Issue 6, 2015, Pages 715-729

  Gallo, Marco ^a   Coutinho, Fiona J ^a,b   Vanner, Robert J ^a,b   Gayden, Tenzin ^c   Mack, Stephen C ^a,b,d   Murison, Alex ^e   Remke, Marc ^a   Li, Ren ^a   Takayama, Naoya ^e   Desai, Kinjal ^f   Lee, Lilian ^a   Lan, Xiaoyang ^a,b   Park, Nicole I ^a,b   Barsyte Lovejoy, Dalia ^e,g   Smil, David ^e,g   Sturm, Dominik ^h   Kushida, Michelle M ^a   Head, Renee ^a   Cusimano, Michael D ^i,j   Bernstein, Mark ^i,k   Clarke, Ian D ^a,l   Dick, John E ^e   Pfister, Stefan M ^h   Rich, Jeremy N ^d   Arrowsmith, Cheryl H ^e,g   Taylor, Michael D ^a,b,i   Jabado, Nada ^c   Bazett Jones, David P ^a   Lupien, Mathieu ^b,e   Dirks, Peter B ^a,b,i   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g Structural Genomics Consortium   (Canada)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j ST MICHAEL'S HOSPITAL   (Canada)

^k TORONTO WESTERN HOSPITAL   (Canada)

^l OCAD UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H3.3; MIXED LINEAGE LEUKEMIA 5 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; HISTONE; MLL5 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL SELF-RENEWAL; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETIC REPRESSION; FETUS; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIMARY CULTURE; PRIORITY JOURNAL; REPRESSOR GENE; SOMATIC MUTATION; TRANSCRIPTION INITIATION SITE; ADOLESCENT; ANIMAL; BRAIN NEOPLASMS; CELL PROLIFERATION; CHILD; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL CULTURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SELF RENEWAL; CHILD; CHILD, PRESCHOOL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; PROGNOSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84959164500     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.10.005     Document Type: Article

References (65)

1. Ahmed K., Li R., Bazett-Jones D.P. Electron spectroscopic imaging of the nuclear landscape. Methods Mol. Biol. 2009, 464:415-423.
2. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
3. Ansari K.I., Mandal S.S. Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J. 2010, 277:1790-1804.
4. Banaszynski L.A., Allis C.D., Lewis P.W. Histone variants in metazoan development. Dev. Cell 2010, 19:662-674.
5. Banaszynski L.A., Wen D., Dewell S., Whitcomb S.J., Lin M., Diaz N., Elsässer S.J., Chapgier A., Goldberg A.D., Canaani E., et al. Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. Cell 2013, 155:107-120.
6. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
7. Bazett-Jones D.P., Li R., Fussner E., Nisman R., Dehghani H. Elucidating chromatin and nuclear domain architecture with electron spectroscopic imaging. Chromosome Res. 2008, 16:397-412.
8. Bjerke L., Mackay A., Nandhabalan M., Burford A., Jury A., Popov S., Bax D.A., Carvalho D., Taylor K.R., Vinci M., et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013, 3:512-519.
9. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477. TCGA Research Network.
10. Bruggeman S.W., Hulsman D., Tanger E., Buckle T., Blom M., Zevenhoven J., van Tellingen O., van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
11. Buenrostro J.D., Giresi P.G., Zaba L.C., Chang H.Y., Greenleaf W.J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 2013, 10:1213-1218.
12. Cadieux B., Ching T.T., VandenBerg S.R., Costello J.F. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006, 66:8469-8476.
13. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
14. Cimadamore F., Amador-Arjona A., Chen C., Huang C.T., Terskikh A.V. SOX2-LIN28/let-7 pathway regulates proliferation and neurogenesis in neural precursors. Proc. Natl. Acad. Sci. USA 2013, 110:E3017-E3026.
15. Cinatl J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int. J. Oncol. 2002, 20:97-106.
16. Deng L.W., Chiu I., Strominger J.L. MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc. Natl. Acad. Sci. USA 2004, 101:757-762.
17. Emerling B.M., Bonifas J., Kratz C.P., Donovan S., Taylor B.R., Green E.D., Le Beau M.M., Shannon K.M. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 2002, 21:4849-4854.
18. Funato K., Major T., Lewis P.W., Allis C.D., Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 2014, 346:1529-1533.
19. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F., Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
20. Gallo M., Ho J., Coutinho F.J., Vanner R., Lee L., Head R., Ling E.K., Clarke I.D., Dirks P.B. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res. 2013, 73:417-427.
21. Garcia J.L., Perez-Caro M., Gomez-Moreta J.A., Gonzalez F., Ortiz J., Blanco O., Sancho M., Hernandez-Rivas J.M., Gonzalez-Sarmiento R., Sanchez-Martin M. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer 2010, 10:454.
22. Gargiulo G., Cesaroni M., Serresi M., de Vries N., Hulsman D., Bruggeman S.W., Lancini C., van Lohuizen M. In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell 2013, 23:660-676.
23. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., de Rooi J.J., Stubbs A.P., Duijm J.E., Daemen A., Bleeker F.E., Bralten L.B., Kloosterhof N.K., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009, 69:9065-9072.
24. Grembecka J., He S., Shi A., Purohit T., Muntean A.G., Sorenson R.J., Showalter H.D., Murai M.J., Belcher A.M., Hartley T., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
25. Hake S.B., Garcia B.A., Duncan E.M., Kauer M., Dellaire G., Shabanowitz J., Bazett-Jones D.P., Allis C.D., Hunt D.F. Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J. Biol. Chem. 2006, 281:559-568.
26. Hashizume R., Andor N., Ihara Y., Lerner R., Gan H., Chen X., Fang D., Huang X., Tom M.W., Ngo V., et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 2014, 20:1394-1396.
27. Heddleston J.M., Wu Q., Rivera M., Minhas S., Lathia J.D., Sloan A.E., Iliopoulos O., Hjelmeland A.B., Rich J.N. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012, 19:428-439.
28. Heuser M., Yap D.B., Leung M., de Algara T.R., Tafech A., McKinney S., Dixon J., Thresher R., Colledge B., Carlton M., et al. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood 2009, 113:1432-1443.
29. Jin C., Felsenfeld G. Distribution of histone H3.3 in hematopoietic cell lineages. Proc. Natl. Acad. Sci. USA 2006, 103:574-579.
30. Jin C., Felsenfeld G. Nucleosome stability mediated by histone variants H3.3 and H2A.Z. Genes Dev. 2007, 21:1519-1529.
31. Jin C., Zang C., Wei G., Cui K., Peng W., Zhao K., Felsenfeld G. H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat. Genet. 2009, 41:941-945.
32. Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193.
33. Khuong-Quang D.A., Buczkowicz P., Rakopoulos P., Liu X.Y., Fontebasso A.M., Bouffet E., Bartels U., Albrecht S., Schwartzentruber J., Letourneau L., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012, 124:439-447.
34. Kim S.J., Son T.G., Kim K., Park H.R., Mattson M.P., Lee J. Interferon-gamma promotes differentiation of neural progenitor cells via the JNK pathway. Neurochem. Res. 2007, 32:1399-1406.
35. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
36. Kreso A., van Galen P., Pedley N.M., Lima-Fernandes E., Frelin C., Davis T., Cao L., Baiazitov R., Du W., Sydorenko N., et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 2014, 20:29-36.
37. Kruidenier L., Chung C.W., Cheng Z., Liddle J., Che K., Joberty G., Bantscheff M., Bountra C., Bridges A., Diallo H., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
38. Laks D.R., Masterman-Smith M., Visnyei K., Angenieux B., Orozco N.M., Foran I., Yong W.H., Vinters H.V., Liau L.M., Lazareff J.A., et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009, 27:980-987.
39. Lathia J.D., Gallagher J., Myers J.T., Li M., Vasanji A., McLendon R.E., Hjelmeland A.B., Huang A.Y., Rich J.N. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS ONE 2011, 6:e24807.
40. Lee S.K., Pfaff S.L. Synchronization of neurogenesis and motor neuron specification by direct coupling of bHLH and homeodomain transcription factors. Neuron 2003, 38:731-745.
41. Lewis P.W., Müller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
42. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
43. Liu J., Wang X.N., Cheng F., Liou Y.C., Deng L.W. Phosphorylation of mixed lineage leukemia 5 by CDC2 affects its cellular distribution and is required for mitotic entry. J. Biol. Chem. 2010, 285:20904-20914.
44. Madan V., Madan B., Brykczynska U., Zilbermann F., Hogeveen K., Döhner K., Döhner H., Weber O., Blum C., Rodewald H.R., et al. Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood 2009, 113:1444-1454.
45. Magnani L., Stoeck A., Zhang X., Lánczky A., Mirabella A.C., Wang T.L., Gyorffy B., Lupien M. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl. Acad. Sci. USA 2013, 110:E1490-E1499.
46. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
47. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
48. Piña B., Suau P. Changes in histones H2A and H3 variant composition in differentiating and mature rat brain cortical neurons. Dev. Biol. 1987, 123:51-58.
49. Pollard S.M., Yoshikawa K., Clarke I.D., Danovi D., Stricker S., Russell R., Bayani J., Head R., Lee M., Bernstein M., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
50. Rheinbay E., Suvà M.L., Gillespie S.M., Wakimoto H., Patel A.P., Shahid M., Oksuz O., Rabkin S.D., Martuza R.L., Rivera M.N., et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013, 3:1567-1579.
51. Rincon-Arano H., Halow J., Delrow J.J., Parkhurst S.M., Groudine M. UpSET recruits HDAC complexes and restricts chromatin accessibility and acetylation at promoter regions. Cell 2012, 151:1214-1228.
52. Schuettengruber B., Chourrout D., Vervoort M., Leblanc B., Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007, 128:735-745.
53. Schuettengruber B., Martinez A.M., Iovino N., Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat. Rev. Mol. Cell Biol. 2011, 12:799-814.
54. Sebastian S., Sreenivas P., Sambasivan R., Cheedipudi S., Kandalla P., Pavlath G.K., Dhawan J. MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. Proc. Natl. Acad. Sci. USA 2009, 106:4719-4724.
55. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
56. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
57. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
58. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tönjes M., Sill M., Bender S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
59. Suvà M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi A.S., Cahill D.P., Nahed B.V., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014, 157:580-594.
60. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
61. Wong G., Goldshmit Y., Turnley A.M. Interferon-gamma but not TNF alpha promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells. Exp. Neurol. 2004, 187:171-177.
62. Wu G., Broniscer A., McEachron T.A., Lu C., Paugh B.S., Becksfort J., Qu C., Ding L., Huether R., Parker M., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 2012, 44:251-253. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
63. Yukawa M., Akiyama T., Franke V., Mise N., Isagawa T., Suzuki Y., Suzuki M.G., Vlahovicek K., Abe K., Aburatani H., Aoki F. Genome-wide analysis of the chromatin composition of histone H2A and H3 variants in mouse embryonic stem cells. PLoS ONE 2014, 9:e92689.
64. Yun H., Damm F., Yap D., Schwarzer A., Chaturvedi A., Jyotsana N., Lübbert M., Bullinger L., Döhner K., Geffers R., et al. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica 2014, 99:1456-1464.
65. Zhang Y., Wong J., Klinger M., Tran M.T., Shannon K.M., Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood 2009, 113:1455-1463.